Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-Fc) (BSCFV-044)

Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD19 specificity or anti-CD64 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can retarget neutrophils to tumor cells. It is designed for the research of B cell lymphoma; Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

CD19 & CD64

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-Fc) (BSCFV-044). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-Fc) (CAT#: BSCFV-044)

Specifications

Targets

Customer Reviews and Q&As